Kynexis
Lauren Cortellessa has a strong background in operations and management across various industries. Lauren has experience in overseeing day-to-day operations, managing renovations, implementing new programs, and training employees. With a background in psychology and a minor in business, Lauren brings a unique perspective to their roles, ensuring successful outcomes and improved efficiencies. Lauren's attention to detail and dedication to excellence have contributed to their success in their various roles within different organizations.
This person is not in any offices
Kynexis
Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the underlying causal human. biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that is potent and highly selective for KAT-II.